Inhibition of smooth muscle cell proliferation and endothelial permeability with flunarizine in vitro and in experimental atheromas.
Repeated weak electrical stimulations of rabbit carotid artery walls with implanted electrodes cause intimal proliferations of smooth muscle cells (SMC) and lead to fibromuscular plaques beneath the anode. If the animals receive a cholesterol-enriched diet the plaques become typical atheromas. The endothelial lining is maintained. The procedure for the production of an atheroma with 11 +/- 4 layers of SMC lasts 4 weeks. Addition of the calcium antagonist Flunarizine to the food during the stimulation periods inhibits the growth of the plaque. The inhibition is dose-dependent. Whether the drug inhibits atherogenesis by direct action on SMC or via an effect on permeation of macromolecules through the endothelium has been studied by measurement of (1) peroxidase (MW 40,000 dalton) permeability through the stimulated endothelium of the artery and (2) the inhibitory effects of Flunarizine on cultures of arterial SMC. Endothelial permeability increases for some hours after stimulation mainly beneath the anode. Flunarizine inhibits the permeation of peroxidase through the endothelial lining for the most part by its action on intercellular transport. The drug also inhibits the growth of SMC in mass cultures and clone cultures. The inhibition of proliferation is not specific for SMC. Skin fibroblasts obtained from the same animals as the artery smooth muscle cells are also inhibited in mass cultures and clone cultures. From the results it can be concluded that Flunarizine exerts its inhibitory action not only by its effect on the permeation through the endothelial lining but by a combined action on permeability and proliferation of cells in the artery wall.
D000818:Animals; D001161:Arteriosclerosis / Q000473:pathology / Q000503:physiopathology*; D002339:Carotid Arteries / Q000187:drug effects / Q000473:pathology / Q000503:physiopathology*; D002455:Cell Division / Q000187:drug effects; D002478:Cells, Cultured; D002936:Cinnarizine / Q000031:analogs & derivatives* / Q000494:pharmacology; D004195:Disease Models, Animal; D004558:Electric Stimulation; D004727:Endothelium / Q000166:cytology / Q000187:drug effects / Q000502:physiology; D005347:Fibroblasts / Q000166:cytology; D005444:Flunarizine; D006735:Horseradish Peroxidase; D008297:Male; D009131:Muscle, Smooth, Vascular / Q000187:drug effects / Q000473:pathology / Q000503:physiopathology*; D011817:Rabbits; D014665:Vasodilator Agents / Q000494:pharmacology*
D014665:Vasodilator Agents; D002936:Cinnarizine; D006735:Horseradish Peroxidase; D005444:Flunarizine